Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
1.57B
-
Number of holders
-
77
-
Total 13F shares, excl. options
-
124M
-
Shares change
-
-27.4M
-
Total reported value, excl. options
-
$67M
-
Value change
-
-$30.5M
-
Put/Call ratio
-
0.48
-
Number of buys
-
26
-
Number of sells
-
-35
-
Price
-
$0.54
Significant Holders of Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) as of Q4 2024
93 filings reported holding ADAP - Adaptimmune Therapeutics PLC - Ordinary Shares as of Q4 2024.
Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) has 77 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 124M shares
of 1.57B outstanding shares and own 7.91% of the company stock.
Largest 10 shareholders include EcoR1 Capital, LLC (27.4M shares), Long Focus Capital Management, LLC (20.5M shares), NEA Management Company, LLC (17.1M shares), Two Seas Capital LP (14.8M shares), BAILLIE GIFFORD & CO (11.8M shares), MPM ASSET MANAGEMENT LLC (5.56M shares), MPM BIOIMPACT LLC (5.1M shares), PFM Health Sciences, LP (4.87M shares), BANK OF AMERICA CORP /DE/ (2.86M shares), and RENAISSANCE TECHNOLOGIES LLC (2.53M shares).
This table shows the top 77 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.